A panel of leading academic and pharmaceutical investigators takes stock of the remarkable work that has been accomplished to date with proteasome inhibitors in cancer, and examines emerging therapeutic possibilities. The topics range from a discussion of the chemistry and cell biology of the proteasome and the rationale for proteasome inhibitors in cancer to a review of current clinical trials underway. The discussion of rationales for testing proteasome inhibitors in cancer models covers the role of the proteasome in NF ...
Read More
A panel of leading academic and pharmaceutical investigators takes stock of the remarkable work that has been accomplished to date with proteasome inhibitors in cancer, and examines emerging therapeutic possibilities. The topics range from a discussion of the chemistry and cell biology of the proteasome and the rationale for proteasome inhibitors in cancer to a review of current clinical trials underway. The discussion of rationales for testing proteasome inhibitors in cancer models covers the role of the proteasome in NF-kB activation, the combining of conventional chemotherapy and radiation with proteasome inhibition, notably PS-341, new proteasome methods of inhibiting viral maturation, and the role of protesome inhibition in the treatment of AIDS. The authors also document the development of bortezomib (VelcadeTM) in Phase I clinical trials and in a multicentered Phase II clinical trials in patients with relapsed and refractory myeloma.
Read Less
Add this copy of Proteasome Inhibitors in Cancer Therapy to cart. $159.69, new condition, Sold by Ingram Customer Returns Center rated 5.0 out of 5 stars, ships from NV, USA, published 2010 by Humana Press Inc..
Add this copy of Proteasome Inhibitors in Cancer Therapy to cart. $168.91, like new condition, Sold by GreatBookPrices rated 4.0 out of 5 stars, ships from Columbia, MD, UNITED STATES, published 2010 by Humana Press Inc..
Choose your shipping method in Checkout. Costs may vary based on destination.
Seller's Description:
Fine. Cancer Drug Discovery and Development . XV, 313 p. Intended for professional and scholarly audience. In Stock. 100% Money Back Guarantee. Brand New, Perfect Condition, allow 4-14 business days for standard shipping. To Alaska, Hawaii, U.S. protectorate, P.O. box, and APO/FPO addresses allow 4-28 business days for Standard shipping. No expedited shipping. All orders placed with expedited shipping will be cancelled. Over 3, 000, 000 happy customers.
Add this copy of Proteasome Inhibitors in Cancer Therapy to cart. $169.16, new condition, Sold by GreatBookPrices rated 4.0 out of 5 stars, ships from Columbia, MD, UNITED STATES, published 2010 by Humana Press Inc..
Choose your shipping method in Checkout. Costs may vary based on destination.
Seller's Description:
New. Cancer Drug Discovery and Development . XV, 313 p. Intended for professional and scholarly audience. In Stock. 100% Money Back Guarantee. Brand New, Perfect Condition, allow 4-14 business days for standard shipping. To Alaska, Hawaii, U.S. protectorate, P.O. box, and APO/FPO addresses allow 4-28 business days for Standard shipping. No expedited shipping. All orders placed with expedited shipping will be cancelled. Over 3, 000, 000 happy customers.
Add this copy of Proteasome Inhibitors in Cancer Therapy to cart. $44.22, very good condition, Sold by UHR Books rated 5.0 out of 5 stars, ships from Hollis Center, ME, UNITED STATES, published 2004 by Humana Press.
Choose your shipping method in Checkout. Costs may vary based on destination.
Seller's Description:
Very Good + Book Discusses the proteasome inhibitors use in cancer therapy, including cancer drug development, chemistry and cell biology of the proteasome, the rationale for proteasome inhibitors in cancer, and clinical trials. Illustrated. From the Cancer Drug Discovery and Development series.